SECsense Logo

Novavax, Inc. 8-K Report: Key Insights as of December 30, 2024

$NVAX
Form 8-K
Filed on: 2024-12-30
Source
Novavax, Inc. 8-K Report: Key Insights as of December 30, 2024

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Entity Information:
  • Company Name: Novavax, Inc.
  • SEC CIK: 0001000694
  • Entity Type: Corporation, specifically a Delaware corporation (DE).
  • Address: 700 Quince Orchard Road, Gaithersburg, MD 20878.
  • Contact Number: 240-268-2000.
  1. Filing Details:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes).
  • Filing Date: December 30, 2024.
  • Filing Reference: 0-26770 (SEC file number).
  • Employer Identification Number (EIN): 22-2816046.
  1. Stock Information:
  • Stock Type: Common Stock.
  • Par Value: $0.01 per share.
  • Ticker Symbol: NVAX (traded on NASDAQ).
  1. Units of Measurement:
  • Financial data is presented in U.S. Dollars (USD) and shares.
  • There is a mention of a measure involving USD per share, indicating an evaluation of stock value or pricing.
  1. Context Information:
  • Reporting Context ID: As of December 30, 2024, indicating this is a snapshot of the company’s financial position on that date.

Summary:

The report is a Form 8-K filed by Novavax, Inc. as of December 30, 2024, detailing potentially significant corporate events. The company operates as a Delaware corporation and is publicly traded under the ticker symbol NVAX on NASDAQ. The filing provides essential corporate and financial identifiers, including contact information and stock details. The context of the filing suggests it pertains to specific disclosures relevant to investors or regulatory bodies at the end of 2024.